Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG-105-12 in Relapsed/Refractory Multiple Myeloma
NCT06999031Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Sep 2024
- Primary completion
- Apr 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CG-105-12 in multiple myeloma (MM), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoints: Incidence of Dose-Limiting Toxicity and Adverse Event Related Laboratory Tests, Vital Signs, Physical Examination up to 12 months. Started Sep 2024; status: recruiting.
02
Drugs
CG-105-12
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06999031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06999031.